Charlotte's Web to Provide CBD to Seniors With Cancer in Pilot Program

Dow Jones03:56

By Elias Schisgall

 

Charlotte's Web Holdings will provide CBD to senior citizens with cancer patients through a pilot program being run by the Center for Medicare and Medicaid Innovation.

The hemp-based CBD wellness company said Thursday that seniors in the program will be able to get CBD reimbursed by Medicare and Medicaid.

The move comes after President Trump signed an executive order reclassifying marijuana as a Schedule III drug. The order is expected to increase the availability of CBD, a non-psychoactive chemical found in cannabis and hemp, for medical research.

Shares soared 59% to a 52-week high of 35 Canadian cents, or 25 U.S. cents, in trading after the order was signed.

Charlotte's Web said it will offer a set of products for patients in the program early next year. The program will be guided by Charlotte's Web's newly-formed Scientific Advisory Board, and the nonprofit Realm of Caring will provide cannabinoid therapy guidance for patients and providers.

"As the CBD market leader and a trusted partner throughout the country among healthcare practitioners, this initiative marks a historic step forward, uniquely positioning Charlotte's Web to expand access to safe, non-intoxicating hemp CBD products through existing pathways," Charlotte's Web Chief Executive Officer Bill Morachnick said.

 

Write to Elias Schisgall at elias.schisgall@wsj.com

 

(END) Dow Jones Newswires

December 18, 2025 14:56 ET (19:56 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment